Bristol Myers Squibb/Johnson & Johnson and Bayer will soon get more hints about whether their Eliquis and Xarelto follow-ons can cut it.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,